Trends in yearly prevalence of third-generation cephalosporin and fluoroquinolone resistant Enterobacteriaceae infections and antimicrobial use in Spanish hospitals, Spain, 1999 to 2010

Eurosurveillance

Volumn 16, Issue 40, 2011, Pages

  Asensio, A ^a   Alvarez Espejo, T ^a   Fernandez Crehuet, J ^b   Ramos, A ^a   Vaque Rafart, J ^c   Bishopberger, C ^d   Hernandez Navarrete M J ^e   Calbo Torrecillas, F ^f   Campayo, J ^g   Canton, R ^h  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d Hospital El Escorial de Madrid   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; DRUG USE; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEMALE; HOSPITAL PATIENT; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD; SPAIN;

EID: 80054715754     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/ese.16.40.19983-en     Document Type: Article

References (18)

1. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med. 2006;119(Suppl 1):S20-8.
2. Luzzaro F, Viganò EF, Fossati D, Grossi A, Sala A, Sturla C, et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol Infect Dis. 2002;21(12):849-55.
3. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41(6):848-54.
4. Podschun R, Ullmann U. Klebsiella spp. as Nosocomial Pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11(4):589-603.
5. Rammelkamp M. Resistance of Staphylococcus aureus to the action of penicillin. Proc Soc Exp Biol Med. 1942;51:386-9.
6. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16(3):128-40.
7. Hawser S, Badal RE, Bouchillon SK, Hoban DJ, Hsueh PR. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study. Int J Antimicrob Agents. 2010;36(3):293-4.
8. Clinical Laboratory Standards Institute (CSLI). Performance standards for antimicrobial susceptibility testing. 20th International Supplement M100-S20. Wayne (PA): CLSI, Jan2010. Available from: http://www.clsi.org/source/orders/free/m100-s20.pdf
9. Arnan M, Gudiol C, Calatayud L, Liñares J, Dominguez MÁ, Batlle M, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis. 2011;30(3):355-60.
10. Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother. 2009; 53(1):235-41.
11. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006; 6(10):629-40.
12. Cantón R, Ruiz-Garbajosa P. Co-resistance: an opportunity for the bacteria and resistance genes. Curr Opin Pharmacol. 2011;11(5):477-485.
13. Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, Suetens C, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother. 2006;58(2):401-407.
14. Szabo D, Silveira F, Fujitani S, Paterson DL. Mechanisms of resistance of bacteria causing ventilator-associated pneumonia. Clin Chest Med. 2005;26(1):75-9.
15. Joseph NM, Sistla S, Dutta TK, Badhe AS, Rasitha D, Parija SC. Ventilator-associated pneumonia in a tertiary care hospital in India: role of multi-drug resistant pathogens. J Infect Dev Ctries 2010;4(4):218-25.
16. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extendedspectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2005;49(5):2137-9.
17. EARS-net. [Accessed 2 Aug 2011]. Available from: http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx
18. Antimicrobial Resistance Surveillance Network (EARS-Net). Annex 2: Country summary sheets. Spain. In: Antimicrobial resistance surveillance in Europe 2009. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: European Centre for Disease Prevention and Control (ECDC); 2010:178-81. [Accessed 2 Aug 2011]. Available from: http://ecdc.europa.eu/en/publications/Publications/1011_SUR_annual_EARS_Net_2009.pdf